Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

Inclusion Criteria:

Patients with stage III-IV HER2 negative breast cancer treated with primary or salvage therapy and now have:

No evidence of disease (NED), or
Stable bone only disease
Patients who have completed standard of care and recovered with mild to no residual toxicity from recent therapy
Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy (excluding bone-directed therapy), prior to enrollment
Patients must be at least 28 days post systemic steroids prior to enrollment
Patients on bisphosphonates, denosumab, and/or endocrine therapy are eligible
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score of =< 1
Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
Estimated life expectancy of more than 6 months
White blood cells (WBC) >= 3000/mm^3 (within 30 days of first vaccination)
Lymphocyte count >= 800/mm^3 (within 30 days of first vaccination)
Platelet count >= 75,000/mm^3 (within 30 days of first vaccination)
Hemoglobin (Hgb) >= 10 g/dl (within 30 days of first vaccination)
Serum creatinine <= 1.2 mg/dl or creatinine clearance > 60 ml/min (within 30 days of first vaccination)
Total bilirubin <= 1.5 mg/dl (within 30 days of first vaccination)
Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) <= 2 times upper limit of normal (ULN) (within 30 days of first vaccination)
Blood glucose < 1.5 ULN (within 30 days of first vaccination)
All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of study

Exclusion Criteria:

Patients with any of the following cardiac conditions:

Symptomatic restrictive cardiomyopathy
Unstable angina within 4 months prior to enrollment
New York Heart Association functional class III-IV heart failure on active treatment
Symptomatic pericardial effusion
Patients at risk for gastrointestinal bleeding (example: peptic ulcer disease, prolonged daily non-steroidal anti-inflammatory use)
Patients with any seizure disorder
Patients with any contraindication to receiving rhuGM-CSF based products
Patients with any clinically significant autoimmune disease uncontrolled with treatment
Patients who are simultaneously enrolled in any other treatment study
Patients who are pregnant or breastfeeding